The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

In what is not exactly a win-win situation for the Indian generic firms, a recent federal court ruling in Delaware, USA, has ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli ...

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...

Mesoblast Ltd (ASX: MSB) shares could still be relatively cheap despite doubling in value according to one leading ...

The Federal Circuit won’t block the launch of MSN Pharmaceuticals Inc.'s copy of the lucrative heart-failure drug Entresto while Novartis Pharmaceuticals Corp. appeals its loss in a patent ...

27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic ...